Abstract
| Lingua originale | English |
|---|---|
| pagine (da-a) | 780-789 |
| Numero di pagine | 10 |
| Rivista | Annals of Neurology |
| Volume | 89 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2021 |
Keywords
- Adolescent
- Young Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized
- COVID-19
- Dimethyl Fumarate
- Female
- Fingolimod Hydrochloride
- Hospitalization
- Humans
- Immunologic Factors
- Immunosuppressive Agents
- Intensive Care Units
- Interferons
- Male
- Middle Aged
- Mortality
- Multiple Sclerosis
- Natalizumab
- SARS-CoV-2
- Severity of Illness Index
- Adult
Fingerprint Entra nei temi di ricerca di 'Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis'. Insieme formano una fingerprint unica.
Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis. / Mirabella, Massimiliano; Lucchini, Matteo; Sormani, Maria P.; De Rossi, Nicola; Schiavetti, Irene; Carmisciano, Luca; Cordioli, Cinzia; Moiola, Lucia; Radaelli, Marta; Immovilli, Paolo; Capobianco, Marco; Trojano, Maria; Zaratin, Paola; Tedeschi, Gioacchino; Comi, Giancarlo; Battaglia, Mario A.; Patti, Francesco; Nozzolillo, Agostino; Bellacosa, Alessandra; Protti, Alessandra; Di Sapio, Alessia; Signori, Alessio; Petrone, Alfredo; Bisecco, Alvino; Iovino, Aniello; Dutto, Anna; Repice, Anna Maria; Conte, Antonella; Bertolotto, Antonio; Bosco, Antonio; Gallo, Antonio; Zito, Antonio; Sartori, Arianna; Giometto, Bruno; Tortorella, Carla; Antozzi, Carlo; Pozzilli, Carlo; Mancinelli, Chiara Rosa; Zanetta, Chiara; Cordano, Christian; Cordioli, Cinzia; Scandellari, Cinzia; Guaschino, Clara; Gasperini, Claudio; Solaro, Claudio; Fioretti, Cristina; Bezzini, Daiana; Marastoni, Damiano; Paolicelli, Damiano; Vecchio, Domizia; Landi, Doriana; Bucciantini, Elisabetta; Pedrazzoli, Elisabetta; Signoriello, Elisabetta; Sbragia, Elvira; Susani, Emanuela Laura; Curti, Erica; Milano, Eva; Marinelli, Fabiana; Camilli, Federico; Boneschi, Filippo Martinelli; Govone, Flora; Bovis, Francesca; Calabria, Francesca; Caleri, Francesca; Rinaldi, Francesca; Vitetta, Francesca; Corea, Francesco; Crescenzo, Francesco; Patti, Francesco; Teatini, Francesco; Tabiadon, Giulietta; Granella, Franco; Boffa, Giacomo; Lus, Giacomo; Brichetto, Giampaolo; Comi, Giancarlo; Tedeschi, Gioacchino; Maniscalco, Giorgia Teresa; Borriello, Giovanna; De Luca, Giovanna; Konrad, Giovanna; Vaula, Giovanna; Marfia, Girolama Alessandra; Mallucci, Giulia; Liberatore, Giuseppe; Salemi, Giuseppe; Miele, Giuseppina; Sibilia, Grazia; Pesci, Ilaria; Schiavetti, Irene; Brambilla, Laura; Lopiano, Leonardo; Sinisi, Leonardo; Pasquali, Livia; Saraceno, Lorenzo; Carmisciano, Luca; Chiveri, Luca; Mancinelli, Luca; Moiola, Lucia; Grimaldi, Luigi M.E.; Caniatti, Luisa Maria; Capobianco, Marco; Cava, Marco Della; Onofrj, Marco; Rovaris, Marco; Salvetti, Marco; Vercellino, Marco; Bragadin, Margherita Monti; Buccafusca, Maria; Buscarinu, Maria Chiara; Celani, Maria Grazia; Grasso, Maria Grazia; Stromillo, Maria Laura; Petracca, Maria; Amato, Maria Pia; Sormani, Maria Pia; L'Episcopo, Maria Rita; Sessa, Maria; Ferrò, Maria Teresa; Trojano, Maria; Ercolani, Maria Vittoria; Bianco, Mariangela; Re, Marianna Lo; Vianello, Marika; Clerico, Marinella; Battaglia, Mario Alberto; Di Napoli, Mario; Ponzano, Marta; Radaelli, Marta; Conti, Marta Zaffira; Calabrese, Massimiliano; Filippi, Massimo; Inglese, Matilde; Pozzato, Matteo; Danni, Maura Chiara; Zaffaroni, Mauro; Zampolini, Mauro; Ponzio, Michela; De Riz, Milena; De Rossi, Nicola; De Stefano, Nicola; Cavalla, Paola; De Mitri, Paola; Grossi, Paola; Zaratin, Paola; Confalonieri, Paolo; Gallo, Paolo; Immovilli, Paolo; Ragonese, Paolo; Sola, Patrizia; Annovazzi, Pietro; Iaffaldano, Pietro; Nardone, Raffaele; Cerqua, Raffaella; Clerici, Raffaella; Lanzillo, Roberta; Motta, Roberta; Balgera, Roberto; Bergamaschi, Roberto; Totaro, Rocco; Iodice, Rosa; Capra, Ruggero; Marangoni, Sabrina; Realmuto, Sabrina; Cottone, Salvatore; Montepietra, Sara; Rasia, Sarah; Arena, Sebastiano; Bucello, Sebastiano; Banfi, Silvia; Bonavita, Simona; Malucchi, Simona; Tonietti, Simone; Vollaro, Stefano; Cordera, Susanna; Aguglia, Umberto; Clerici, Valentina Torri; Barcella, Valeria; Bergamaschi, Valeria; Morra, Vincenzo Brescia; Dattola, Vincenzo; Mantero, Vittorio.
In: Annals of Neurology, Vol. 89, 2021, pag. 780-789.Risultato della ricerca: Contributo in rivista › Articolo in rivista › peer review
TY - JOUR
T1 - Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
AU - Mirabella, Massimiliano
AU - Lucchini, Matteo
AU - Sormani, Maria P.
AU - De Rossi, Nicola
AU - Schiavetti, Irene
AU - Carmisciano, Luca
AU - Cordioli, Cinzia
AU - Moiola, Lucia
AU - Radaelli, Marta
AU - Immovilli, Paolo
AU - Capobianco, Marco
AU - Trojano, Maria
AU - Zaratin, Paola
AU - Tedeschi, Gioacchino
AU - Comi, Giancarlo
AU - Battaglia, Mario A.
AU - Patti, Francesco
AU - Nozzolillo, Agostino
AU - Bellacosa, Alessandra
AU - Protti, Alessandra
AU - Di Sapio, Alessia
AU - Signori, Alessio
AU - Petrone, Alfredo
AU - Bisecco, Alvino
AU - Iovino, Aniello
AU - Dutto, Anna
AU - Repice, Anna Maria
AU - Conte, Antonella
AU - Bertolotto, Antonio
AU - Bosco, Antonio
AU - Gallo, Antonio
AU - Zito, Antonio
AU - Sartori, Arianna
AU - Giometto, Bruno
AU - Tortorella, Carla
AU - Antozzi, Carlo
AU - Pozzilli, Carlo
AU - Mancinelli, Chiara Rosa
AU - Zanetta, Chiara
AU - Cordano, Christian
AU - Cordioli, Cinzia
AU - Scandellari, Cinzia
AU - Guaschino, Clara
AU - Gasperini, Claudio
AU - Solaro, Claudio
AU - Fioretti, Cristina
AU - Bezzini, Daiana
AU - Marastoni, Damiano
AU - Paolicelli, Damiano
AU - Vecchio, Domizia
AU - Landi, Doriana
AU - Bucciantini, Elisabetta
AU - Pedrazzoli, Elisabetta
AU - Signoriello, Elisabetta
AU - Sbragia, Elvira
AU - Susani, Emanuela Laura
AU - Curti, Erica
AU - Milano, Eva
AU - Marinelli, Fabiana
AU - Camilli, Federico
AU - Boneschi, Filippo Martinelli
AU - Govone, Flora
AU - Bovis, Francesca
AU - Calabria, Francesca
AU - Caleri, Francesca
AU - Rinaldi, Francesca
AU - Vitetta, Francesca
AU - Corea, Francesco
AU - Crescenzo, Francesco
AU - Patti, Francesco
AU - Teatini, Francesco
AU - Tabiadon, Giulietta
AU - Granella, Franco
AU - Boffa, Giacomo
AU - Lus, Giacomo
AU - Brichetto, Giampaolo
AU - Comi, Giancarlo
AU - Tedeschi, Gioacchino
AU - Maniscalco, Giorgia Teresa
AU - Borriello, Giovanna
AU - De Luca, Giovanna
AU - Konrad, Giovanna
AU - Vaula, Giovanna
AU - Marfia, Girolama Alessandra
AU - Mallucci, Giulia
AU - Liberatore, Giuseppe
AU - Salemi, Giuseppe
AU - Miele, Giuseppina
AU - Sibilia, Grazia
AU - Pesci, Ilaria
AU - Schiavetti, Irene
AU - Brambilla, Laura
AU - Lopiano, Leonardo
AU - Sinisi, Leonardo
AU - Pasquali, Livia
AU - Saraceno, Lorenzo
AU - Carmisciano, Luca
AU - Chiveri, Luca
AU - Mancinelli, Luca
AU - Moiola, Lucia
AU - Grimaldi, Luigi M.E.
AU - Caniatti, Luisa Maria
AU - Capobianco, Marco
AU - Cava, Marco Della
AU - Onofrj, Marco
AU - Rovaris, Marco
AU - Salvetti, Marco
AU - Vercellino, Marco
AU - Bragadin, Margherita Monti
AU - Buccafusca, Maria
AU - Buscarinu, Maria Chiara
AU - Celani, Maria Grazia
AU - Grasso, Maria Grazia
AU - Stromillo, Maria Laura
AU - Petracca, Maria
AU - Amato, Maria Pia
AU - Sormani, Maria Pia
AU - L'Episcopo, Maria Rita
AU - Sessa, Maria
AU - Ferrò, Maria Teresa
AU - Trojano, Maria
AU - Ercolani, Maria Vittoria
AU - Bianco, Mariangela
AU - Re, Marianna Lo
AU - Vianello, Marika
AU - Clerico, Marinella
AU - Battaglia, Mario Alberto
AU - Di Napoli, Mario
AU - Ponzano, Marta
AU - Radaelli, Marta
AU - Conti, Marta Zaffira
AU - Calabrese, Massimiliano
AU - Filippi, Massimo
AU - Inglese, Matilde
AU - Pozzato, Matteo
AU - Danni, Maura Chiara
AU - Zaffaroni, Mauro
AU - Zampolini, Mauro
AU - Ponzio, Michela
AU - De Riz, Milena
AU - De Rossi, Nicola
AU - De Stefano, Nicola
AU - Cavalla, Paola
AU - De Mitri, Paola
AU - Grossi, Paola
AU - Zaratin, Paola
AU - Confalonieri, Paolo
AU - Gallo, Paolo
AU - Immovilli, Paolo
AU - Ragonese, Paolo
AU - Sola, Patrizia
AU - Annovazzi, Pietro
AU - Iaffaldano, Pietro
AU - Nardone, Raffaele
AU - Cerqua, Raffaella
AU - Clerici, Raffaella
AU - Lanzillo, Roberta
AU - Motta, Roberta
AU - Balgera, Roberto
AU - Bergamaschi, Roberto
AU - Totaro, Rocco
AU - Iodice, Rosa
AU - Capra, Ruggero
AU - Marangoni, Sabrina
AU - Realmuto, Sabrina
AU - Cottone, Salvatore
AU - Montepietra, Sara
AU - Rasia, Sarah
AU - Arena, Sebastiano
AU - Bucello, Sebastiano
AU - Banfi, Silvia
AU - Bonavita, Simona
AU - Malucchi, Simona
AU - Tonietti, Simone
AU - Vollaro, Stefano
AU - Cordera, Susanna
AU - Aguglia, Umberto
AU - Clerici, Valentina Torri
AU - Barcella, Valeria
AU - Bergamaschi, Valeria
AU - Morra, Vincenzo Brescia
AU - Dattola, Vincenzo
AU - Mantero, Vittorio
PY - 2021
Y1 - 2021
N2 - Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results. Results: Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID-19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty-eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized. After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti-CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18–4.74, p = 0.015) with increased risk of severe COVID-19. Recent use (<1 month) of methylprednisolone was also associated with a worse outcome (OR = 5.24, 95% CI = 2.20–12.53, p = 0.001). Results were confirmed by the PS-weighted analysis and by all the sensitivity analyses. Interpretation: This study showed an acceptable level of safety of therapies with a broad array of mechanisms of action. However, some specific elements of risk emerged. These will need to be considered while the COVID-19 pandemic persists. ANN NEUROL 2021;89:780–789.
AB - Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS). Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requiring hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evaluated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score (PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results. Results: Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID-19, 13 (1.54%) died; 11 of them were in a progressive MS phase, and 8 were without any therapy. Thirty-eight (4.5%) were admitted to an ICU; 99 (11.7%) had radiologically documented pneumonia; 96 (11.4%) were hospitalized. After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body mass index, comorbidities, and recent methylprednisolone use, therapy with an anti-CD20 agent (ocrelizumab or rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18–4.74, p = 0.015) with increased risk of severe COVID-19. Recent use (<1 month) of methylprednisolone was also associated with a worse outcome (OR = 5.24, 95% CI = 2.20–12.53, p = 0.001). Results were confirmed by the PS-weighted analysis and by all the sensitivity analyses. Interpretation: This study showed an acceptable level of safety of therapies with a broad array of mechanisms of action. However, some specific elements of risk emerged. These will need to be considered while the COVID-19 pandemic persists. ANN NEUROL 2021;89:780–789.
KW - Adolescent
KW - Young Adult
KW - Aged
KW - Aged, 80 and over
KW - Antibodies, Monoclonal, Humanized
KW - COVID-19
KW - Dimethyl Fumarate
KW - Female
KW - Fingolimod Hydrochloride
KW - Hospitalization
KW - Humans
KW - Immunologic Factors
KW - Immunosuppressive Agents
KW - Intensive Care Units
KW - Interferons
KW - Male
KW - Middle Aged
KW - Mortality
KW - Multiple Sclerosis
KW - Natalizumab
KW - SARS-CoV-2
KW - Severity of Illness Index
KW - Adult
KW - Adolescent
KW - Young Adult
KW - Aged
KW - Aged, 80 and over
KW - Antibodies, Monoclonal, Humanized
KW - COVID-19
KW - Dimethyl Fumarate
KW - Female
KW - Fingolimod Hydrochloride
KW - Hospitalization
KW - Humans
KW - Immunologic Factors
KW - Immunosuppressive Agents
KW - Intensive Care Units
KW - Interferons
KW - Male
KW - Middle Aged
KW - Mortality
KW - Multiple Sclerosis
KW - Natalizumab
KW - SARS-CoV-2
KW - Severity of Illness Index
KW - Adult
UR - http://hdl.handle.net/10807/176940
U2 - 10.1002/ana.26028
DO - 10.1002/ana.26028
M3 - Article
VL - 89
SP - 780
EP - 789
JO - Annals of Neurology
JF - Annals of Neurology
SN - 0364-5134
ER -